title: C5L2: a controversial receptor of complement anaphylatoxin, C5a.
abstract: C5a is the paramount proinflammatory mediator of the complement cascade, and has been previously thought to act only through a single, G-protein-coupled, C5a receptor (C5aR; also termed CD88). In 2000, a second C5a receptor, C5L2 (previously known as GPR77), was discovered; yet, despite 12 yr of intensive research, its biological, or pathophysiological, function is both enigmatic and controversial. Unlike C5aR, this receptor does not couple to G proteins, and early studies promoted the hypothesis that C5L2 functions as a decoy receptor. However, recent data have provided other evidence for more complicated and conflicting interactions between C5L2 and other inflammatory mediators. C5L2 has been recently demonstrated to physically interact with both C5aR and β-arrestin to negatively regulate C5aR signaling toward an anti-inflammatory manner, and to reduce pathology, in several disease models in vivo. In direct contrast, other groups have demonstrated that C5L2 stimulation caused release of HMGB1 both in vitro and in vivo, and enhanced pathology in sepsis models, suggesting a clear proinflammatory signaling role. These astoundingly contradictory data challenge our precepts and complicate the foundational bases for the possible targeting of C5L2 as a therapeutic option in inflammatory disease. C5L2 may be the great masquerader in complement biology; its function dependent on the cell type, species, and disease context. Because of these unusual and unforeseen complexities, we present the current state of knowledge on C5L2 structure, expression and, most controversially, its putative functions.-Li, R., Coulthard, L.G., Wu, M. C. L., Taylor, S. M., Woodruff, T. M. C5L2: a controversial receptor of complement anaphylatoxin, C5a.
authors.affiliation: School of Biomedical Sciences, University of Queensland, St Lucia, QLD, 4072, Australia.
authors.forename: Rui
authors.initials: R
authors.lastname: Li
authors.forename: Liam G
authors.initials: LG
authors.lastname: Coulthard
authors.forename: M C L
authors.initials: MC
authors.lastname: Wu
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Taylor
authors.forename: Trent M
authors.initials: TM
authors.lastname: Woodruff
mesh_terms: D000818:Animals; D019390:Arrestins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D015936:Complement C5a / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000235:genetics / Q000276:immunology; D006801:Humans; D017434:Protein Structure, Tertiary; D044087:Receptor, Anaphylatoxin C5a; D019707:Receptors, Chemokine / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D011951:Receptors, Complement / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D018805:Sepsis / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D015398:Signal Transduction; D000071557:beta-Arrestins
chemical_list: D019390:Arrestins; C488033:C5AR1 protein, human; C417003:C5aR2 protein, human; D044087:Receptor, Anaphylatoxin C5a; D019707:Receptors, Chemokine; D011951:Receptors, Complement; D000071557:beta-Arrestins; D015936:Complement C5a